Clinical significance of APOB inactivation in hepatocellular carcinoma |
Lee, Gena
(Department of Systems Biology, The University of Texas MD Anderson Cancer Center)
Jeong, Yun Seong (Department of Systems Biology, The University of Texas MD Anderson Cancer Center) Kim, Do Won (Department of Systems Biology, The University of Texas MD Anderson Cancer Center) Kwak, Min Jun (Department of Systems Biology, The University of Texas MD Anderson Cancer Center) Koh, Jiwon (Department of Pathology, Seoul National University College of Medicine) Joo, Eun Wook (Department of Gynecology, School of Medicine, Kyung Hee University) Lee, Ju-Seog (Department of Systems Biology, The University of Texas MD Anderson Cancer Center) Kah, Susie (Department of Internal Medicine, School of Medicine, Kyung Hee University) Sim, Yeong-Eun (Department of Internal Medicine, School of Medicine, Kyung Hee University) Yim, Sun Young (Department of Systems Biology, The University of Texas MD Anderson Cancer Center) |
1 | Watanabe, S., Horie, Y. & Suzuki, A. Hepatocyte-specific Pten-deficient mice as a novel model for nonalcoholic steatohepatitis and hepatocellular carcinoma. Hepatol. Res. 33, 161-166 (2005). DOI |
2 | Wang, L. et al. Epigenetic and genetic alterations of PTEN in hepatocellular carcinoma. Hepatol. Res. 37, 389-396 (2007). DOI |
3 | Chin, L. & Gray, J. W. Translating insights from the cancer genome into clinical practice. Nature 452, 553-563 (2008). DOI |
4 | Torre, L. A. et al. Global cancer statistics, 2012. CA Cancer J. Clin. 65, 87-108 (2015). DOI |
5 | Wilhelm, S. et al. Discovery and development of sorafenib: a multikinase inhibitor for treating. Nat. Rev. Drug Discov. 5, 835-844 (2006). DOI |
6 | Whittaker, S., Marais, R. & Zhu, A. X. The role of signaling pathways in the development and treatment of hepatocellular carcinoma. Oncogene 29, 4989-5005 (2010). DOI |
7 | Wu, S. K. et al. Expression of PTEN, PPM1A and P-Smad2 in hepatocellular carcinomas and adjacent. World J. Gastroenterol. 13, 4554-4559 (2007). DOI |
8 | Qiu, W. et al. Phosphatase and tensin homolog (PTEN) regulates hepatic lipogenesis, microsomal triglyceride transfer protein, and the secretion of apolipoprotein B-containing lipoproteins. Hepatology 48, 1799-1809 (2008). DOI |
9 | Wang, F. B., Zhu, C. L., Liu, X. & Gao, G. S. HBV inhibits apoB production via the suppression of MTP expression. Lipids Health Dis. 10, 207 (2011). DOI |
10 | Forner, A., Llovet, J. M. & Bruix, J. Hepatocellular carcinoma. Lancet 379, 1245-1255 (2012). DOI |
11 | Jemal, A. et al. Cancer statistics, 2008. CA Cancer J. Clin. 58, 71-96 (2008). DOI |
12 | Siegel, R. L., Miller, K. D. & Jemal, A. Cancer statistics, 2017. CA Cancer J. Clin. 67, 7-30 (2017). DOI |
13 | El-Serag, H. B. Hepatocellular carcinoma: recent trends in the United States. Gastroenterology 127, S27-S34 (2004). DOI |
14 | Shaw, J. J. & Shah, S. A. Rising incidence and demographics of hepatocellular carcinoma in the USA: what does it mean? Expert Rev. Gastroenterol. Hepatol. 5, 365-370 (2011). DOI |
15 | Bruix, J. et al. Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 389, 56-66 (2017). DOI |
16 | Llovet, J. M. et al. Sorafenib in advanced hepatocellular carcinoma. N. Engl. J. Med. 359, 378-390 (2008). DOI |
17 | Totoki, Y. et al. High-resolution characterization of a hepatocellular carcinoma genome. Nat. Genet. 43, 464-469 (2011). DOI |
18 | Guichard, C. et al. Integrated analysis of somatic mutations and focal copynumber changes identifies. Nat. Genet. 44, 694-698 (2012). DOI |
19 | Huang, J. et al. Exome sequencing of hepatitis B virus-associated hepatocellular carcinoma. Nat. Genet. 44, 1117-1121 (2012). DOI |
20 | Cleary, S. P. et al. Identification of driver genes in hepatocellular carcinoma by exome sequencing. Hepatology 58, 1693-1702 (2013). DOI |
21 | Fujimoto, A. et al. Whole-genome mutational landscape and characterization of noncoding and structural mutations in liver cancer. Nat. Genet. 48, 500-509 (2016). DOI |
22 | Schonfeld, G. Familial hypobetalipoproteinemia: a review. J. Lipid Res. 44, 878-883 (2003). DOI |
23 | Lee, J. S. The mutational landscape of hepatocellular carcinoma. Clin. Mol. Hepatol. 21, 220-229 (2015). DOI |
24 | Lee, J. S. Exploring cancer genomic data from the cancer genome atlas project. BMB Rep. 49, 607-611 (2016). DOI |
25 | Consortium, T. Comprehensive and integrative genomic characterization of hepatocellular carcinoma. Cell 169, 1327-1341 (2017). DOI |
26 | Lonardo, A., Tarugi, P., Ballarini, G. & Bagni, A. Familial heterozygous hypobetalipoproteinemia, extrahepatic primary malignancy. Dig. Dis. Sci. 43, 2489-2492 (1998). DOI |
27 | Lee, J. S. et al. Application of comparative functional genomics to identify bestfit mouse models to study human cancer. Nat. Genet. 36, 1306-1311 (2004). DOI |
28 | Lee, J. S. et al. A novel prognostic subtype of human hepatocellular carcinoma derived from hepatic progenitor cells. Nat. Med. 12, 410-416 (2006). DOI |
29 | Park, Y. Y. et al. Yes-associated protein 1 and transcriptional coactivator with PDZ-binding motif activate the mammalian target of rapamycin complex 1 pathway by regulating amino acid transporters in hepatocellular carcinoma. Hepatology 63, 159-172 (2016). DOI |
30 | Tadin-Strapps, M. et al. siRNA-induced liver ApoB knockdown lowers serum LDL-cholesterol in a mouse model. J. Lipid Res. 52, 1084-1097 (2011). DOI |
31 | Thorgeirsson, S. S., Lee, J. S. & Grisham, J. W. Functional genomics of hepatocellular carcinoma. Hepatology 43, S145-S150 (2006). DOI |
32 | Dong, B. et al. Activating CAR and beta-catenin induces uncontrolled liver growth and. Nat. Commun. 6, 5944 (2015). DOI |
33 | Lim, H. Y. et al. Prediction of disease-free survival in hepatocellular carcinoma by gene. Ann. Surg. Oncol. 20, 3747-3753 (2013). DOI |
34 | Roessler, S. et al. A unique metastasis gene signature enables prediction of tumor relapse in. Cancer Res. 70, 10202-10212 (2010). DOI |
35 | Roessler, S. et al. Integrative genomic identification of genes on 8p associated with hepatocellular. Gastroenterology 142, 957-966 (2012). DOI |
36 | Lee, J. S. et al. Classification and prediction of survival in hepatocellular carcinoma by gene expression profiling. Hepatology 40, 667-676 (2004). DOI |
37 | Woo, H. G. et al. Gene expression-based recurrence prediction of hepatitis B virus-related human hepatocellular carcinoma. Clin. Cancer Res. 14, 2056-2064 (2008). DOI |
38 | Kim, S. M. et al. Sixty-five gene-based risk score classifier predicts overall survival in hepatocellular carcinoma. Hepatology 55, 1443-1452 (2012). DOI |
39 | Kim, J. H. et al. Genomic predictors for recurrence patterns of hepatocellular carcinoma: model derivation and validation. PLoS Med. 11, e1001770 (2014). DOI |
40 | Sohn, B. H. et al. Inactivation of Hippo pathway is significantly associated with poor prognosis in hepatocellular carcinoma. Clin. Cancer Res. 22, 1256-1264 (2016). DOI |
41 | Oh, S. C. et al. Clinical and genomic landscape of gastric cancer with a mesenchymal phenotype. Nat. Commun. 9, 1777 (2018). DOI |
42 | Simon, R. et al. Analysis of gene expression data using BRB-ArrayTools. Cancer Inform. 3, 11-17 (2007). |
43 | Eisen, M. B., Spellman, P. T., Brown, P. O. & Botstein, D. Cluster analysis and display of genome-wide expression patterns. Proc. Natl. Acad. Sci. USA 95, 14863-14868 (1998). DOI |
44 | Cefalu, A. B. et al. A novel APOB mutation identified by exome sequencing cosegregates with steatosis, liver cancer, and hypocholesterolemia. Arterioscler. Thromb. Vasc. Biol. 33, 2021-2025 (2013). DOI |
45 | Kaposi-Novak, P. et al. Met-regulated expression signature defines a subset of human hepatocellular carcinomas with poor prognosis and aggressive phenotype. J. Clin. Invest. 116, 1582-1595 (2006). DOI |
46 | Ahn, S. M. et al. Genomic portrait of resectable hepatocellular carcinomas: implications of RB1 and FGF19 aberrations for patient stratification. Hepatology 60, 1972-1982 (2014). DOI |
47 | Fujimoto, A. et al. Whole-genome sequencing of liver cancers identifies etiological influences on. Nat. Genet. 44, 760-764 (2012). DOI |
48 | Bonnefont-Rousselot, D. et al. Cryptogenic cirrhosis in a patient with familial hypocholesterolemia due to a new truncated form of apolipoprotein B. Eur. J. Gastroenterol. Hepatol. 21, 104-108 (2009). DOI |
49 | Welty, F. K. Hypobetalipoproteinemia and abetalipoproteinemia. Curr. Opin. Lipidol. 25, 161-168 (2014). DOI |
50 | Tarugi, P. & Lonardo, A. Heterozygous familial hypobetalipoproteinemia associated with fatty liver. Am. J. Gastroenterol. 92, 1400-1402 (1997). |
51 | Lonardo, A., Tarugi, P., Ballarini, G. & Bagni, A. Familial heterozygous hypobetalipoproteinemia, extrahepatic primary malignancy, and hepatocellular carcinoma. Dig. Dis. Sci. 43, 2489-2492 (1998). DOI |
52 | Hegele, R. A. Plasma lipoproteins: genetic influences and clinical implications. Nat. Rev. Genet. 10, 109-121 (2009). |
53 | Stiles, B. et al. Liver-specific deletion of negative regulator Pten results in fatty liver and insulin hypersensitivity [corrected]. Proc. Natl. Acad. Sci. USA 101, 2082-2087 (2004). DOI |
![]() |